The FDA recently issued a statement warning the public of the risks and potential false results obtained with noninvasive prenatal screening tests, noting that inappropriate usage and interpretation has resulted in improper medical decisions.
Many new therapies have been developed over the past decade to treat disorders that are often present at birth and early treatment can lead to better outcomes. However, the screenings for newborns have been slow to adapt.
In this exclusive video interview, Michal Elovitz, MD, chief medical advisor at Mirvie, discusses the latest data from the RNA testing platform in predicting preterm birth at the SMFM 42nd Annual Pregnancy Meeting.
Maneesh Jain, CEO and co-founder of Mirvie, a proprietary RNA platform that uses blood samples to predict pregnancy complications such as preeclampsia, sits down with Contemporary OB/GYN to discuss the potential of the test.
A study in the journal Ultrasound in Obstetrics & Gynecology1 has found that noninvasive prenatal testing (NIPT) can help in the early detection of a set of single gene disorders (SGDs), especially in the presence of either abnormal ultrasound findings or a family history.
Pregnant women do not believe that noninvasive prenatal testing (NIPT) is an obligation of responsible motherhood, according to a qualitative study that investigated the impact of NIPT on women's moral beliefs about the meaning of prenatal screening.
Clinicians should carefully consider using noninvasive prenatal testing (NIPT) for the screening of chromosomal abnormalities in twin pregnancies because the combined positive predictive value (PPV) is limited and the screening efficiency is not stable, according to a prospective study.